search
Back to results

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Primary Purpose

Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma

Status
Terminated
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Niraparib combined with MGD013
Sponsored by
Zai Lab (Shanghai) Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signed written informed consent form.
  2. ≥ 18 years old.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  4. Subjects who have at least one measurable lesion according to RECIST v1.1 criterion (only applicable for subjects at dose expansion part).
  5. Subjects with adequate organ function.
  6. Subjects with life expectancy of 12 weeks or more.

Inclusion criteria for different indications:

Dose escalation part and EXP-1 gastric cancer (including gastroesophageal junction cancer)

  1. Subjects with histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;
  2. Subjects who have previously failed at least 2 prior systemic treatment for locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; treatment failure is defined as the occurrence of disease progression or intolerable adverse events during treatment. Subjects who have progressed on first-line chemotherapy with platinum and fluoropyrimidine for advanced disease, and who are deemed unfit/ineligible for further chemotherapy or anti-angiogenesis therapy may also be eligible;

EXP-2 triple negative breast cancer (TNBC)

  1. Subjects with metastatic or inoperable locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression based on most recently analyzed biopsy or archived tissue;
  2. Subjects with disease progression or relapse after ≥ 2 prior lines of standard chemotherapy regimens in the locally advanced or metastatic disease stage (if the disease is progressed to unresectable locally advanced or metastatic disease within 12 months after adjuvant or neoadjuvant chemotherapy for limited-stage disease, it can be counted as 1 prior line);
  3. Subjects with LAG-3 expression meeting the criteria of moderate or high expression (confirmed by the central laboratory);
  4. Subjects who have undergone prior taxane therapy regardless of disease stage (adjuvant, neoadjuvant, or advanced) at the time of treatment; or subjects who are not eligible for taxane therapy because of contraindications;

EXP-3 biliary tract carcinoma

  1. Subjects with histologically confirmed, surgically unresectable locally advanced, recurrent or metastatic biliary track carcinoma (BTC), including cholangiocarcinoma or gallbladder carcinoma;
  2. Subjects with disease progression or relapse after ≥ 1 prior standard chemotherapy regimen. If the patient received preoperative neoadjuvant chemotherapy or adjuvant chemotherapy after R0 radical resection, and the disease progression occurred during the chemotherapy or within 6 months after discontinuation of chemotherapy, it may be counted as first-line treatment failure;
  3. Subjects with LAG3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory);
  4. Subjects without known IDH-1 mutations or FGFR2 fusions (if status is unknown, the subject will be included without the need for active testing).

EXP-4 endometrial carcinoma

  1. Subjects with histologically confirmed advanced or metastatic endometrial carcinoma;
  2. Subjects with disease progression or relapse after ≥ 1 prior standard chemotherapy regimen in the advanced or metastatic stage;
  3. Subjects with LAG-3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory);
  4. Subjects without carcinosarcomas, endometrial leiomyosarcomas, or other high-grade sarcomas, or endometrial stromal sarcomas.

Exclusion criteria:

  1. Known hypersensitivity to niraparib or active or inactive ingredients of drugs with similar chemical structure to niraparib.
  2. Subjects who have previously received PARP inhibitors (including niraparib) treatment; anti-LAG-3 treatment.
  3. Subjects who have received treatment with other investigational drugs within 4 weeks prior to the first dose of study drug or < 5 elimination half-lives of the investigational drug (whichever is longer); subjects who have underwent a major surgery within 4 weeks prior to the start of study, or with any surgical side effects that have not been recovered.
  4. Subjects who experienced ≥ Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy, which lasted more than 4 weeks.
  5. Subjects who experienced transfusion dependent anemia or thrombocytopenia, including:

    • Blood (platelet or red blood cell) transfusion within 2 weeks prior to the first dose;
    • Subjects who previously received colony stimulating factor treatment (e.g., granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF) or recombinant erythropoietin) within 2 weeks prior to the first dose.
  6. Untreated or symptomatic brain metastases or leptomeningeal metastases (e.g., new or worsening symptoms or vital signs, or unstable dose of hormones required). Note: There is no need for the imaging scan to confirm absence of brain metastases; subjects with spinal cord compression who have previously received definitive therapy and have an evidence for clinically stable disease at least > 28 days can be enrolled.
  7. Subjects who have received palliative radiotherapy on > 20% bone marrow area within 3 weeks prior to enrollment.
  8. Subjects who have other invasive cancers (except treated in situ cancer, non-melanoma skin cancer, localized prostate cancer (Gleason score < 6), etc.) other than gastric cancer, endometrial carcinoma, biliary tract carcinoma and breast cancer within 5 years prior to enrollment.
  9. Subjects who have been previously or are currently diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  10. Subjects who have severe or uncontrolled diseases, including but not limited to:

    • Digestive tract hemorrhage within 2 months prior to enrollment or currently active digestive tract hemorrhage;
    • Uncontrolled nausea and vomiting, inability to swallow the investigational drugs, or any gastrointestinal diseases that may intervene with and influence drug absorption and metabolism;
    • Human immunodeficiency virus (HIV) infection, active hepatitis (e.g., hepatitis B (HBV-DNA > 500 IU/ml), hepatitis C virus ribonucleic acid (HCV-RNA) positive);
    • Uncontrolled ventricular arrhythmia, myocardial infarction that occurred within 3 months prior to enrollment;
    • Uncontrolled grand mal seizure, unstable spinal cord compression, superior vena cava syndrome or other mental disorders influencing subjects to sign informed consent forms;
    • Immunodeficiency (except splenectomy).
  11. Subjects with known or suspected history of autoimmune disease, except: vitiligo and psoriasis that does not require systemic treatment (in recent two years); subjects with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
  12. Treatment with systemic corticosteroids (≥ 10 mg/day prednisone or equivalent) or other immunosuppressive drugs within 14 days prior to the initiation of the study treatment.
  13. If patients who have previously used immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) have the following adverse events related to immune checkpoint inhibitors, they will be not suitable for inclusion regardless of recovered or not:

    • ≥ Grade 3 eye-related adverse events;
    • Abnormal hepatic function met Hy's Law criteria;
    • ≥ Grade 3 neurotoxicity;
    • ≥ Grade 3 colitis;
    • ≥ Grade 3 renal toxicity.
  14. Subjects with a history of pneumonitis requiring steroid treatment or current pneumonitis.
  15. Subjects with previous or current disease, treatment, or laboratory abnormality that may intervene with study results and affect subjects participating in the study, or subjects not suitable for participation in the study at the investigator's discretion.

Sites / Locations

  • Beijing Cancer Hospital
  • Sun Yat-Sen University Cancer Center
  • Henan Cancer Hospital
  • Henan Cancer Hospital
  • Hubei Cancer Hospital
  • Liaoning Cancer hospital
  • First Affiliated Hospital of Xi'an Jiaotong University
  • Obstetrics & Gynecology Hospital of Fudan University
  • Sichuan Cancer Hospital
  • TianJin Medical University General Hospital
  • The First Affiliated Hospital Zhejiang University School Of Medicine
  • Beijing Cancer Hospital
  • Sun Yat-Sen University Cancer Center
  • The Affiliated Tumor Hospital of Harbin Medical University
  • The Chinese University of Hong Kong, Prince of Wales Hospital
  • The University of Hong Kong, Queen Mary Hospital
  • Taizhou Hospital of Zhejiang Province
  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
  • Sir Run Shaw Hospital, School Of Medicine ,Zhejiang University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Assigned Interventions

Arm Description

Niraparib combined with MGD013

Outcomes

Primary Outcome Measures

Safety and Validity profiles
Phase I Dose Escalation Part: To determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer; To determine the recommended phase II dose (RP2D) of niraparib in combination with MGD013 in patients with advanced or metastatic solid tumors.
Validity profiles
Phase I Dose Expansion Part: • To assess the objective response rate (ORR) of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors.

Secondary Outcome Measures

Safety and Validity profiles
Phase I Dose Escalation Part: To assess the safety and tolerability of different doses levels of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer; To assess the preliminary antitumor activity of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer, including objective response rate (ORR), disease control rate (DCR), etc.
Safety and Validity profiles
Phase I Dose Expansion Part: To assess other antitumor activity of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors, including duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS); To assess the safety and tolerability of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors. To assess the antitumor activity of niraparib in combination with MGD013 in patients with different HRR gene status, expression level of PD-L1 and LAG-3.
Exploratory objective
To explore the correlation between other biomarkers related to MGD013/niraparib and subject safety, antitumor activity.

Full Information

First Posted
November 25, 2019
Last Updated
May 25, 2022
Sponsor
Zai Lab (Shanghai) Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04178460
Brief Title
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Official Title
A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Terminated
Why Stopped
This termination decision is a business decision and is not due to any safety concerns.
Study Start Date
February 3, 2020 (Actual)
Primary Completion Date
March 2, 2022 (Actual)
Study Completion Date
March 2, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zai Lab (Shanghai) Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or Metastatic Solid Tumor Who Failed Prior Treatment. This study consists of dose escalation part and dose expansion part.'3+3'design will be adopted in the dose escalation part in subjects with advanced or metastatic gastric cancer who failed prior treatment. The dose of niraparib will be fixed and determined based on baseline weight and platelet count of subjects. Dose expansion part will be expanded at the specified dose level to further assess the safety and preliminary antitumor activity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Assigned Interventions
Arm Type
Experimental
Arm Description
Niraparib combined with MGD013
Intervention Type
Drug
Intervention Name(s)
Niraparib combined with MGD013
Intervention Description
The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level. For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation).
Primary Outcome Measure Information:
Title
Safety and Validity profiles
Description
Phase I Dose Escalation Part: To determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer; To determine the recommended phase II dose (RP2D) of niraparib in combination with MGD013 in patients with advanced or metastatic solid tumors.
Time Frame
approximately 45months
Title
Validity profiles
Description
Phase I Dose Expansion Part: • To assess the objective response rate (ORR) of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors.
Time Frame
approximately 45months
Secondary Outcome Measure Information:
Title
Safety and Validity profiles
Description
Phase I Dose Escalation Part: To assess the safety and tolerability of different doses levels of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer; To assess the preliminary antitumor activity of niraparib in combination with MGD013 in patients with advanced or metastatic gastric cancer, including objective response rate (ORR), disease control rate (DCR), etc.
Time Frame
approximately 45months
Title
Safety and Validity profiles
Description
Phase I Dose Expansion Part: To assess other antitumor activity of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors, including duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and overall survival (OS); To assess the safety and tolerability of niraparib in combination with MGD013 in patients with different types of advanced or metastatic solid tumors. To assess the antitumor activity of niraparib in combination with MGD013 in patients with different HRR gene status, expression level of PD-L1 and LAG-3.
Time Frame
approximately 45months
Title
Exploratory objective
Description
To explore the correlation between other biomarkers related to MGD013/niraparib and subject safety, antitumor activity.
Time Frame
approximately 45months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written informed consent form. ≥ 18 years old. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. Subjects who have at least one measurable lesion according to RECIST v1.1 criterion (only applicable for subjects at dose expansion part). Subjects with adequate organ function. Subjects with life expectancy of 12 weeks or more. Inclusion criteria for different indications: Dose escalation part and EXP-1 gastric cancer (including gastroesophageal junction cancer) Subjects with histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; Subjects who have previously failed at least 2 prior systemic treatment for locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; treatment failure is defined as the occurrence of disease progression or intolerable adverse events during treatment. Subjects who have progressed on first-line chemotherapy with platinum and fluoropyrimidine for advanced disease, and who are deemed unfit/ineligible for further chemotherapy or anti-angiogenesis therapy may also be eligible; EXP-2 triple negative breast cancer (TNBC) Subjects with metastatic or inoperable locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression based on most recently analyzed biopsy or archived tissue; Subjects with disease progression or relapse after ≥ 2 prior lines of standard chemotherapy regimens in the locally advanced or metastatic disease stage (if the disease is progressed to unresectable locally advanced or metastatic disease within 12 months after adjuvant or neoadjuvant chemotherapy for limited-stage disease, it can be counted as 1 prior line); Subjects with LAG-3 expression meeting the criteria of moderate or high expression (confirmed by the central laboratory); Subjects who have undergone prior taxane therapy regardless of disease stage (adjuvant, neoadjuvant, or advanced) at the time of treatment; or subjects who are not eligible for taxane therapy because of contraindications; EXP-3 biliary tract carcinoma Subjects with histologically confirmed, surgically unresectable locally advanced, recurrent or metastatic biliary track carcinoma (BTC), including cholangiocarcinoma or gallbladder carcinoma; Subjects with disease progression or relapse after ≥ 1 prior standard chemotherapy regimen. If the patient received preoperative neoadjuvant chemotherapy or adjuvant chemotherapy after R0 radical resection, and the disease progression occurred during the chemotherapy or within 6 months after discontinuation of chemotherapy, it may be counted as first-line treatment failure; Subjects with LAG3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory); Subjects without known IDH-1 mutations or FGFR2 fusions (if status is unknown, the subject will be included without the need for active testing). EXP-4 endometrial carcinoma Subjects with histologically confirmed advanced or metastatic endometrial carcinoma; Subjects with disease progression or relapse after ≥ 1 prior standard chemotherapy regimen in the advanced or metastatic stage; Subjects with LAG-3 expression meeting the criteria for moderate or high expression (confirmed by the central laboratory); Subjects without carcinosarcomas, endometrial leiomyosarcomas, or other high-grade sarcomas, or endometrial stromal sarcomas. Exclusion criteria: Known hypersensitivity to niraparib or active or inactive ingredients of drugs with similar chemical structure to niraparib. Subjects who have previously received PARP inhibitors (including niraparib) treatment; anti-LAG-3 treatment. Subjects who have received treatment with other investigational drugs within 4 weeks prior to the first dose of study drug or < 5 elimination half-lives of the investigational drug (whichever is longer); subjects who have underwent a major surgery within 4 weeks prior to the start of study, or with any surgical side effects that have not been recovered. Subjects who experienced ≥ Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy, which lasted more than 4 weeks. Subjects who experienced transfusion dependent anemia or thrombocytopenia, including: Blood (platelet or red blood cell) transfusion within 2 weeks prior to the first dose; Subjects who previously received colony stimulating factor treatment (e.g., granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF) or recombinant erythropoietin) within 2 weeks prior to the first dose. Untreated or symptomatic brain metastases or leptomeningeal metastases (e.g., new or worsening symptoms or vital signs, or unstable dose of hormones required). Note: There is no need for the imaging scan to confirm absence of brain metastases; subjects with spinal cord compression who have previously received definitive therapy and have an evidence for clinically stable disease at least > 28 days can be enrolled. Subjects who have received palliative radiotherapy on > 20% bone marrow area within 3 weeks prior to enrollment. Subjects who have other invasive cancers (except treated in situ cancer, non-melanoma skin cancer, localized prostate cancer (Gleason score < 6), etc.) other than gastric cancer, endometrial carcinoma, biliary tract carcinoma and breast cancer within 5 years prior to enrollment. Subjects who have been previously or are currently diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Subjects who have severe or uncontrolled diseases, including but not limited to: Digestive tract hemorrhage within 2 months prior to enrollment or currently active digestive tract hemorrhage; Uncontrolled nausea and vomiting, inability to swallow the investigational drugs, or any gastrointestinal diseases that may intervene with and influence drug absorption and metabolism; Human immunodeficiency virus (HIV) infection, active hepatitis (e.g., hepatitis B (HBV-DNA > 500 IU/ml), hepatitis C virus ribonucleic acid (HCV-RNA) positive); Uncontrolled ventricular arrhythmia, myocardial infarction that occurred within 3 months prior to enrollment; Uncontrolled grand mal seizure, unstable spinal cord compression, superior vena cava syndrome or other mental disorders influencing subjects to sign informed consent forms; Immunodeficiency (except splenectomy). Subjects with known or suspected history of autoimmune disease, except: vitiligo and psoriasis that does not require systemic treatment (in recent two years); subjects with a history of Grave's disease that are now euthyroid clinically and by laboratory testing. Treatment with systemic corticosteroids (≥ 10 mg/day prednisone or equivalent) or other immunosuppressive drugs within 14 days prior to the initiation of the study treatment. If patients who have previously used immune checkpoint inhibitors (such as anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) have the following adverse events related to immune checkpoint inhibitors, they will be not suitable for inclusion regardless of recovered or not: ≥ Grade 3 eye-related adverse events; Abnormal hepatic function met Hy's Law criteria; ≥ Grade 3 neurotoxicity; ≥ Grade 3 colitis; ≥ Grade 3 renal toxicity. Subjects with a history of pneumonitis requiring steroid treatment or current pneumonitis. Subjects with previous or current disease, treatment, or laboratory abnormality that may intervene with study results and affect subjects participating in the study, or subjects not suitable for participation in the study at the investigator's discretion.
Facility Information:
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Sun Yat-Sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450000
Country
China
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
Country
China
Facility Name
Hubei Cancer Hospital
City
Wuhan
State/Province
Hubei
Country
China
Facility Name
Liaoning Cancer hospital
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
Country
China
Facility Name
Obstetrics & Gynecology Hospital of Fudan University
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
Sichuan Cancer Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Facility Name
TianJin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Facility Name
The First Affiliated Hospital Zhejiang University School Of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Facility Name
Beijing Cancer Hospital
City
Beijing
Country
China
Facility Name
Sun Yat-Sen University Cancer Center
City
Guangzhou
Country
China
Facility Name
The Affiliated Tumor Hospital of Harbin Medical University
City
Ha'erbin
Country
China
Facility Name
The Chinese University of Hong Kong, Prince of Wales Hospital
City
Hong Kong
Country
China
Facility Name
The University of Hong Kong, Queen Mary Hospital
City
Hong Kong
Country
China
Facility Name
Taizhou Hospital of Zhejiang Province
City
Taizhou
Country
China
Facility Name
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
City
Wuhan
Country
China
Facility Name
Sir Run Shaw Hospital, School Of Medicine ,Zhejiang University
City
Zhejiang
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

We'll reach out to this number within 24 hrs